Startseite>>Signaling Pathways>> DNA Damage/DNA Repair>> Deubiquitinase>>IU1-47

IU1-47

Katalog-Nr.GC64956

IU1-47 ist ein potenter und spezifischer USP14-Inhibitor mit einem IC50 von 0,6 μM.

Products are for research use only. Not for human use. We do not sell to patients.

IU1-47 Chemische Struktur

Cas No.: 670270-31-2

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
148,50 $
Auf Lager
5mg
135,00 $
Auf Lager
10mg
207,00 $
Auf Lager
25mg
423,00 $
Auf Lager
50mg
675,00 $
Auf Lager
100mg
1.080,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

IU1-47 is a potent and specific USP14 inhibitor with an IC50 of 0.6 μM. IU1-47 inhibits IsoT/USP5 with an IC50 of 20 μM. IU1-47 induces tau elimination in cultured neurons[1].

IU1-47 is essentially inactive on free USP14 (USP14 that is not bound to the proteasome). IU1-47 (25 μM) antagonizes USP14 deubiquitinating activity and stimulates substrate degradation in vitro[1]. IU1-47 stimulates tau degradation principally via the ubiquitin-proteasome system. IU1-47 (3 μM, 10 and 30 μM; 48 hours) significantly decreases Tau and phosphotau species Ser-202/Thr-205 levels in murine cortical primary neurons. The level of USP14 itself does not change[1].

[1]. Boselli M, et al. An inhibitor of the proteasomal deubiquitinating enzyme USP14 induces tau elimination in cultured neurons. J Biol Chem. 2017 Nov 24;292(47):19209-19225.

Bewertungen

Review for IU1-47

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for IU1-47

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.